Top

Published in:

01-07-2015 | Editors' Invited Manuscript

Current challenges in designing GBM trials for immunotherapy

Authors: Shiao-Pei Weathers, Mark R. Gilbert

Published in: Journal of Neuro-Oncology | Issue 3/2015

Abstract

Immune system modulation is evolving into a promising treatment modality in glioblastoma. Our growing understanding of glioma immunobiology has fueled efforts to develop immunotherapeutic strategies to combat this lethal primary brain tumor. Autologous stimulated lymphocytes, immunotherapy with cytokines and dendritic cells, immune checkpoint inhibitors, virotherapy, and tumor or peptide based vaccines are immunotherapy approaches under active investigation. A number of challenges are evident in the design of immunotherapy clinical trials in glioblastoma including patient selection, immune and imaging response monitoring, and evaluation of clinical outcome.

Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996PubMedCrossRef

Gilbert MR et al (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 31(32):4085–4091PubMedCentralPubMedCrossRef

Barker CF, Billingham RE (1977) Immunologically privileged sites. Adv Immunol 25:1–54PubMedCrossRef

Jackson CM, Lim M, Drake CG (2014) Immunotherapy for brain cancer: recent progress and future promise. Clin Cancer Res 20(14):3651–3659PubMedCrossRef

Fabry Z, Raine CS, Hart MN (1994) Nervous tissue as an immune compartment: the dialect of the immune response in the CNS. Immunol Today 15(5):218–224PubMedCrossRef

Galea I, Bechmann I, Perry VH (2007) What is immune privilege (not)? Trends Immunol 28(1):12–18PubMedCrossRef

Dunn GP, Dunn IF, Curry WT (2007) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun 7:12PubMedCentralPubMed

Bullard DE et al (1986) Immunobiology of human gliomas. Semin Oncol 13(1):94–109PubMed

Owens T et al (1994) Inflammatory cytokines in the brain: does the CNS shape immune responses? Immunol Today 15(12):566–571PubMedCrossRef

10.

Stevens A, Kloter I, Roggendorf W (1988) Inflammatory infiltrates and natural killer cell presence in human brain tumors. Cancer 61(4):738–743PubMedCrossRef

11.

Drake CG (2010) Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 10(8):580–593PubMedCentralPubMedCrossRef

12.

Lipson EJ, Drake CG (2011) Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 17(22):6958–6962PubMedCentralPubMedCrossRef

13.

Brooks WH et al (1972) Depressed cell-mediated immunity in patients with primary intracranial tumors characterization of a humoral immunosuppressive factor. J Exp Med 136(6):1631–1647PubMedCentralPubMedCrossRef

14.

Wrann M et al (1987) T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. EMBO J 6(6):1633–1636PubMedCentralPubMed

15.

Munn DH, Mellor AL (2004) IDO and tolerance to tumors. Trends Mol Med 10(1):15–18PubMedCrossRef

16.

Platten M, Wick W, Weller M (2001) Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech 52(4):401–410PubMedCrossRef

17.

Roszman T, Elliott L, Brooks W (1991) Modulation of T-cell function by gliomas. Immunol Today 12(10):370–374PubMedCrossRef

18.

Tada M et al (1993) Human glioblastoma cells produce 77 amino acid interleukin-8 (IL-8(77)). J Neurooncol 16(1):25–34PubMedCrossRef

19.

Charles NA et al (2011) The brain tumor microenvironment. Glia 59(8):1169–1180PubMedCrossRef

20.

Heimberger AB et al (2002) Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 50(1):158–164 discussion 164–6PubMed

21.

Wheeler CJ et al (2004) Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 10(16):5316–5326PubMedCrossRef

22.

Yu JS et al (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64(14):4973–4979PubMedCrossRef

23.

Liau LM et al (2000) Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case report. Neurosurg Focus 9(6):e8PubMedCrossRef

24.

Wong AJ et al (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89(7):2965–2969PubMedCentralPubMedCrossRef

25.

Sampson JH et al (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28(31):4722–4729PubMedCentralPubMedCrossRef

26.

Sampson JH et al (2011) Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 13(3):324–333PubMedCentralPubMedCrossRef

27.

Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12(4):269–281PubMedCrossRef

28.

Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723PubMedCentralPubMedCrossRef

29.

Robert C et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517–2526PubMedCrossRef

30.

Lebbe C et al (2010) Ipilimumab improves survival in previously treated, advanced melanoma patients with poor prognostic factors: subgroup analysis from a phase III trial. Annu Oncol 21:401

31.

Schartz NE et al (2010) Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res 20(3):247–250PubMed

32.

Fecci PE et al (2007) Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 13(7):2158–2167PubMedCrossRef

33.

Grauer OM et al (2007) CD4+ FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 121(1):95–105PubMedCrossRef

34.

Jiang H et al (2014) Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One 9(5):e97407PubMedCentralPubMedCrossRef

35.

Russell SJ, Peng KW, Bell JC (2012) Oncolytic virotherapy. Nat Biotechnol 30(7):658–670PubMedCrossRef

36.

Melcher A et al (2011) Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 19(6):1008–1016PubMedCentralPubMedCrossRef

37.

Fueyo J et al (2003) Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 95(9):652–660PubMedCrossRef

38.

Jiang H et al (2007) Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst 99(18):1410–1414PubMedCrossRef

39.

Jiang H et al (2011) Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activity. J Virol 85(10):4720–4729PubMedCentralPubMedCrossRef

40.

Li Y et al (2008) Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res 68(17):6889–6895PubMedCentralPubMedCrossRef

41.

Uhl M et al (2009) Autophagy within the antigen donor cell facilitates efficient antigen cross-priming of virus-specific CD8+ T cells. Cell Death Differ 16(7):991–1005PubMedCrossRef

42.

Heimberger AB, Sampson JH (2011) Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol 13(1):3–13PubMedCentralPubMedCrossRef

43.

Carro MS et al (2010) The transcriptional network for mesenchymal transformation of brain tumours. Nature 463(7279):318–325PubMedCentralPubMedCrossRef

44.

Freije WA et al (2004) Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64(18):6503–6510PubMedCrossRef

45.

Murat A et al (2008) Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26(18):3015–3024PubMedCrossRef

46.

Suntharalingam G et al (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355(10):1018–1028PubMedCrossRef

47.

Wen PY et al (2010) Response assessment challenges in clinical trials of gliomas. Curr Oncol Rep 12(1):68–75PubMedCrossRef

48.

Weber JS, Kahler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30(21):2691–2697PubMedCrossRef

49.

Topalian SL et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020–1030PubMedCrossRef

50.

Liao B et al (2014) Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 16(4):589–593PubMedCentralPubMedCrossRef

51.

Wikstrand CJ, Bigner DD (1981) Hyperimmunization of non-human primates with BCG-CW and cultured human glioma-derived cells: production of reactive antisera and absence of EAE induction. J Neuroimmunol 1(3):249–260PubMedCrossRef

52.

Lammert A et al (2013) Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy. Exp Clin Endocrinol Diabetes 121(10):581–587PubMedCrossRef

53.

Orgogozo JM et al (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61(1):46–54PubMedCrossRef

54.

Zitvogel L et al (2013) Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39(1):74–88PubMedCrossRef

55.

Kroemer G et al (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31:51–72PubMedCrossRef

Title: Current challenges in designing GBM trials for immunotherapy
Authors: Shiao-Pei Weathers
Mark R. Gilbert
Publication date: 01-07-2015
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2015
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-015-1716-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Current challenges in designing GBM trials for immunotherapy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2015

Glioblastoma antigen discovery—foundations for immunotherapy

Introduction: brain tumor immunotherapy

Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials

The role of IDO in brain tumor immunotherapy

Glioblastoma stem cells and stem cell-targeting immunotherapies

The role of checkpoints in the treatment of GBM